Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 9, 2012, Pages 2186-2195

  Insalaco, Lavinia ^a   Di Gaudio, Francesca ^a   Terrasi, Marianna ^a   Amodeo, Valeria ^a   Caruso, Stefano ^a   Corsini, Lidia Rita ^a   Fanale, Daniele ^a   Margarese, Naomi ^a   Santini, Daniele ^b   Bazan, Viviana ^a   Russo, Antonio ^a,c  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c Institute for Cancer Research and Molecular Medicine and Center of Biotechnology   (Italy)

Author keywords

Breast cancer; FN1; Invasion; TGF 1; THBS 1; ZOL

Indexed keywords

EID: 84865405372     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01527.x     Document Type: Article

References (56)

1. Mundy GR. Mechanisms of bone metastasis. Cancer. 1997; 80: 1546-56.
2. Lipton A, Steger GG, Figueroa J, et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res. 2008; 14: 6690-6.
3. Yoneda T, Sasaki A, Dunstan C, et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest. 1997; 99: 2509-17.
4. Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000; 60: 2949-54.
5. Denoyelle C, Hong L, Vannier JP, et al. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer. 2003; 88: 1631-40.
6. Oades GM, Senaratne SG, Clarke IA, et al. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol. 2003; 170: 246-52.
7. Stresing V, Daubine F, Benzaid I, et al. Bisphosphonates in cancer therapy. Cancer Lett. 2007; 257: 16-35.
8. Monkkonen H, Auriola S, Lehenkari P, et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol. 2006; 147: 437-45.
9. Clezardin P, Fournier P, Boissier S, et al. In vitro and in vivo antitumour effects of bisphosphonates. Curr Med Chem. 2003; 10: 173-80.
10. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res. 2002; 8: 1080-4.
11. Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 2003; 9: 2893-7.
12. Melani C, Sangaletti S, Barazzetta FM, et al. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumour-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumour stroma. Cancer Res. 2007; 67: 11438-46.
13. Bissell MJ, Rizki A, Mian IS. Tissue architecture: the ultimate regulator of breast epithelial function. Curr Opin Cell Biol. 2003; 15: 753-62.
14. Weaver VM, Petersen OW, Wang F, et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol. 1997; 137: 231-45.
15. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods. 2003; 30: 256-68.
16. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995; 1: 27-31.
17. Su E, Han X, Jiang G. The transforming growth factor beta 1/SMAD signaling pathway involved in human chronic myeloid leukemia. Tumori. 2010; 96: 659-66.
18. Markowitz SD, Roberts AB. Tumour suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev. 1996; 7: 93-102.
19. Ariazi EA, Satomi Y, Ellis MJ, et al. Activation of the transforming growth factor beta signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol. Cancer Res. 1999; 59: 1917-28.
20. Si XH, Yang LJ. Extraction and purification of TGFbeta and its effect on the induction of apoptosis of hepatocytes. World J Gastroenterol. 2001; 7: 527-31.
21. Bornstein P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J Cell Biol. 1995; 130: 503-6.
22. Dawson DW, Volpert OV, Pearce SF, et al. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol. 1999; 55: 332-8.
23. Dawson DW, Pearce SF, Zhong R, et al. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol. 1997; 138: 707-17.
24. Chandrasekaran S, Guo NH, Rodrigues RG, et al. Pro-adhesive and chemotactic activities of thrombospondin-1 for breast carcinoma cells are mediated by alpha3beta1 integrin and regulated by insulin-like growth factor-1 and CD98. J Biol Chem. 1999; 274: 11408-16.
25. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008; 214: 199-210.
26. Guo N, Templeton NS, Al-Barazi H, et al. Thrombospondin-1 promotes alpha3beta1 integrin-mediated adhesion and neurite-like outgrowth and inhibits proliferation of small cell lung carcinoma cells. Cancer Res. 2000; 60: 457-66.
27. Sage EH, Bornstein P. Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondin. J Biol Chem. 1991; 266: 14831-4.
28. Ramaswamy S, Ross KN, Lander ES, et al. A molecular signature of metastasis in primary solid tumours. Nat Genet. 2003; 33: 49-54.
29. Qiu TH, Chandramouli GV, Hunter KW, et al. Global expression profiling identifies signatures of tumour virulence in MMTV-PyMT-transgenic mice: correlation to human disease. Cancer Res. 2004; 64: 5973-81.
30. Feng Y, Sun B, Li X, et al. Differentially expressed genes between primary cancer and paired lymph node metastases predict clinical outcome of node-positive breast cancer patients. Breast Cancer Res Treat. 2007; 103: 319-29.
31. Calvo A, Catena R, Noble MS, et al. Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumour growth and lung metastasis. Oncogene. 2008; 27: 5373-84.
32. Ma XJ, Dahiya S, Richardson E, et al. Gene expression profiling of the tumour microenvironment during breast cancer progression. Breast Cancer Res. 2009; 11: R7.
33. Yi B, Williams PJ, Niewolna M, et al. Tumour-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res. 2002; 62: 917-23.
34. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002; 62: 6538-44.
35. Gautier L, Cope L, Bolstad BM, et al. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004; 20: 307-15.
36. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003; 4: 249-64.
37. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004; 3: Article3.
38. Benjamini Y, Drai D, Elmer G, et al. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001; 125: 279-84.
39. Wettenhall JM, Simpson KM, Satterley K, et al. affylmGUI: a graphical user interface for linear modeling of single channel microarray data. Bioinformatics. 2006; 22: 897-9.
40. Caraglia M, Marra M, Leonetti C, et al. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. J Cell Physiol. 2007; 211: 533-43.
41. Coxon JP, Oades GM, Kirby RS, et al. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int. 2004; 94: 164-70.
42. Sato K, Kimura S, Segawa H, et al. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer. 2005; 116: 94-9.
43. Marra M, Santini D, Meo G, et al. Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells. Int J Cancer. 2009; 125: 2004-13.
44. Caraglia M, D'Alessandro AM, Marra M, et al. The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. Oncogene. 2004; 23: 6900-13.
45. Facchini G, Caraglia M, Morabito A, et al. Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial. Cancer Biol Ther. 2010; 10: 543-8.
46. Aft R, Naughton M, Trinkaus K, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 2010; 11: 421-8.
47. Ungefroren H, Groth S, Sebens S, et al. Differential roles of Smad2 and Smad3 in the regulation of TGF-beta1-mediated growth inhibition and cell migration in pancreatic ductal adenocarcinoma cells: control by Rac1. Mol Cancer. 2011; 10: 67.
48. Massague J, Gomis RR. The logic of TGFbeta signaling. FEBS Lett. 2006; 580: 2811-20.
49. Miyazono K, Suzuki H, Imamura T. Regulation of TGF-beta signaling and its roles in progression of tumours. Cancer Sci. 2003; 94: 230-4.
50. ten Dijke P, Hill CS. New insights into TGF-beta-Smad signalling. Trends Biochem Sci. 2004; 29: 265-73.
51. Backman U, Svensson A, Christofferson RH, et al. The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumour angiogenesis. Anticancer Res. 2008; 28: 1551-7.
52. Soltau J, Zirrgiebel U, Esser N, et al. Antitumoural and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model. Anticancer Res. 2008; 28: 933-41.
53. Li YY, Chang JW, Chou WC, et al. Zoledronic acid is unable to induce apoptosis, but slows tumour growth and prolongs survival for non-small-cell lung cancers. Lung Cancer. 2008; 59: 180-91.
54. Karabulut B, Erten C, Gul MK, et al. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Cell Biol Int. 2009; 33: 239-46.
55. Horii Y, Takei H, Koibuchi Y, et al. The regulatory effect of tamoxifen on fibronectin expression in oestrogen-dependent MCF-7 breast carcinoma cells. Oncol Rep. 2006; 15: 1191-5.
56. Landstrom M, Bergh A, Thornell LE, et al. Oestrogen treatment of Dunning tumours in castrated rats: qualitative and quantitative morphology. Prostate. 1992; 20: 199-211.